Please ensure Javascript is enabled for purposes of website accessibility

Catalent and Johnson & Johnson Sign Coronavirus Vaccine Manufacturing Deal

By Jim Crumly – Updated Apr 29, 2020 at 2:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Catalent expects to be ready to manufacture the drug giant's lead COVID-19 vaccine by January.

Shares of drug manufacturer Catalent (CTLT 4.81%) were up by 10% at 2 p.m. Wednesday after the company announced it had signed an agreement with the Janssen Pharmaceuticals subsidiary of Johnson & Johnson (JNJ 0.86%) to manufacture a COVID-19 vaccine. The agreement includes joint investment in expanding the capacity of Catalent's Bloomington, Indiana manufacturing facility. The financial terms of the deal were not disclosed.

Catalent plans to hire 300 workers for the plant starting in July and be ready to support a 24/7 manufacturing schedule by January. The 875,000 square-foot Bloomington facility has expertise in drug substance development and manufacture, and the company said the scale-up would involve the use of high-speed machines for vial filling and carton loading.

Vial-filling machine.

Image source: Getty Images.

Johnson & Johnson has said that its goal is to rapidly supply more than 1 billion doses of a SARS-CoV-2 vaccine globally on a not-for-profit basis, but the company has yet to start human trials of its lead vaccine candidate. Phase 1 clinical studies are scheduled to start in September, but Johnson & Johnson said that it was planning to begin manufacture of the medicine "at risk" for emergency use, which should position it with a large supply pending the outcome of the studies.

Last week, Johnson & Johnson announced it had signed a manufacturing agreement with Emergent BioSolutions (EBS 3.90%) worth $135 million for contract development and manufacturing services for the COVID-19 vaccine. Shares of Emergent were falling Wednesday on the Catalent news, but it's likely the two deals complement each other, with Emergent producing the drug substance itself in a facility that's partnered with the Department of Health and Human Services for that purpose.

 

Jim Crumly owns shares of Emergent BioSolutions and Johnson & Johnson. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$166.36 (0.86%) $1.42
Catalent, Inc. Stock Quote
Catalent, Inc.
CTLT
$76.24 (4.81%) $3.50
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$21.33 (3.90%) $0.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.